VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+26.97%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$922M
AUM Growth
+$922M
(+36%)
Cap. Flow
+$293M
Cap. Flow
% of AUM
31.79%
Top 10 Holdings %
Top 10 Hldgs %
73.15%
Holding
32
New
7
Increased
7
Reduced
5
Closed
4
Top Buys
| 1 |
Instil Bio
TIL
|
$172M |
| 2 |
Cullinan Oncology
CGEM
|
$49M |
| 3 |
Aclaris Therapeutics
ACRS
|
$44.5M |
| 4 |
Pharvaris
PHVS
|
$25.3M |
| 5 |
ESSA Pharma
EPIX
|
$18.2M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$18.5M |
| 2 |
Altimmune
ALT
|
$14.1M |
| 3 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$13.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$11.7M |
| 5 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
$9.39M |
Sector Composition
| 1 | Healthcare | 89.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Instil Bio
TIL
$182M
| $172M | 18.68% | +6,865,076 | New | +$172M |
|
|
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $94M | 10.19% | 4,016,873 | – | – |
|
|
3
Aclaris Therapeutics
ACRS
$209M
| $93.8M | 10.17% | 3,720,582 +1,765,650 | +90% | +$44.5M |
|
4
Olema Pharmaceuticals
OLMA
$375M
| $51M | 5.53% | 1,536,193 | – | – |
|
|
5
Altimmune
ALT
$338M
| $49.5M | 5.37% | 3,500,000 -1,000,000 | -22% | -$14.1M |
|
|
6
Cullinan Oncology
CGEM
$445M
| $49M | 5.32% | +1,176,145 | New | +$49M |
|
|
KNTE
7
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $45.9M | 4.98% | 1,473,014 | – | – |
|
|
TRIL
8
DELISTED
Trillium Therapeutics Inc.
TRIL
| $43.4M | 4.71% | 4,040,000 | – | – |
|
|
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $40.9M | 4.44% | 2,641,809 +52,868 | +2% | +$818K |
|
10
VistaGen Therapeutics
VTGN
$102M
| $34.7M | 3.77% | 16,302,596 +6,942,596 | +74% | +$14.8M |
|
11
Athira Pharma
ATHA
$15.3M
| $31.1M | 3.38% | 1,691,623 | – | – |
|
12
Relmada Therapeutics
RLMD
$37.2M
| $30M | 3.26% | 853,206 +184,766 | +28% | +$6.51M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $25.6M | 2.77% | 1,240,610 +440,610 | +55% | +$9.08M |
|
|
14
Pharvaris
PHVS
$1.39B
| $25.3M | 2.75% | +902,882 | New | +$25.3M |
|
|
15
Keros Therapeutics
KROS
$618M
| $22.9M | 2.49% | 372,306 -300,000 | -45% | -$18.5M |
|
|
16
ESSA Pharma
EPIX
$11.4M
| $18.2M | 1.97% | +625,754 | New | +$18.2M |
|
17
Kura Oncology
KURA
$686M
| $16.3M | 1.76% | 575,000 | – | – |
|
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $13.2M | 1.44% | 591,782 -523,473 | -47% | -$11.7M |
|
19
Adicet Bio
ACET
$59.9M
| $13.1M | 1.42% | +1,000,000 | New | +$13.1M |
|
|
APTO
20
DELISTED
Aptose Biosciences, Inc.
APTO
| $9.59M | 1.04% | +1,605,400 | New | +$9.59M |
|
21
Cogent Biosciences
COGT
$1.69B
| $9.56M | 1.04% | 1,088,817 | – | – |
|
22
Aligos Therapeutics
ALGS
$73.3M
| $9.29M | 1.01% | 408,377 +3,471 | +0.9% | +$78.9K |
|
23
EyePoint Pharmaceuticals
EYPT
$797M
| $7.11M | 0.77% | +700,000 | New | +$7.11M |
|
24
Tango Therapeutics
TNGX
$747M
| $5.56M | 0.6% | 500,000 | – | – |
|
|
MTCR
25
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $4.22M | 0.46% | 680,000 -13,673 | -2% | -$84.8K |
|